Raltegravir-based regimens are effective in HIV-1 group O-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 1, 2012, Pages

  Depatureaux, Agnès ^a,b   Leoz, Marie ^a,b   Le Moal, Gwenae ^c   Pathé, Jean Paul ^d   Pavie, Juliette ^e   Batisse, Dominique ^f   Daneluzzi, Vincent ^g   Genet, Philippe ^h   Gerard, Laurence ^e   Lascaux Cametz, Anne Sophie ⁱ   Lambolez, Tessa ^j   Chennebault, Jean Marie ^k   Plantier, Jean Christophe ^a,b  

^a HÔPITAL CHARLES NICOLLE   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d CHI Eure Seine   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g Service des Maladies Infectieuses   (France)

^h CENTRE HOSPITALIER VICTOR DUPOUY   (France)

ⁱ Service d'Immunologie Clinique   (France)

^j CHG de Longjumeau   (France)

^k ANGERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE; RALTEGRAVIR; TENOFOVIR; TIPRANAVIR;

ADULT; AGED; ANTIVIRAL RESISTANCE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LETTER; LIPODYSTROPHY; MALE; PRIORITY JOURNAL; VIROLOGY;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84865758396     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31826327c4     Document Type: Letter

References (25)

1. Gueudin M, Plantier JC, Lemee V, et al. Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J Acquir Immune Defic Syndr. 2007;44:500-505.
2. Plantier JC, Djemai M, Lemee V, et al. Census and analysis of persistent false-negative results in serological diagnosis of human immunodeficiency virus type 1 group O infections. J Clin Microbiol. 2009;47:2906-2911.
3. Roques P, Robertson DL, Souquiere S, et al. Phylogenetic analysis of 49 newly derived HIV-1 group O strains: high viral diversity but no group M-like subtype structure. Virology. 2002;302:259-273.
4. Descamps D, Collin G, Letourneur F, et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol. 1997;71:8893-8898.
5. Tuaillon E, Gueudin M, Lemee V, et al. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J Acquir Immune Defic Syndr. 2004;37:1543-1549.
6. Depatureaux A, Charpentier C, Collin G, et al. Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide. Antimicrob Agents Chemother. 2010;54:4016-4019.
7. Depatureaux A, Charpentier C, Leoz M, et al. Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M. J Acquir Immune Defic Syndr. 2011;56:139-145.
8. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drugresistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis. 2010;50:605-612.
9. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43: 509-515.
10. FDA notifications. Raltegravir indication extended for treatment-naive patients. AIDS Alert. 2009;24:93.
11. Leoz M, Depatureaux A, Vessiere A, et al. Integrase polymorphism and HIV-1 group O diversity. AIDS. 2008;22:1239-1243.
12. Briz V, Garrido C, Poveda E, et al. Raltegravir and etravirine are active against HIV type 1 group O. AIDS Res Hum Retroviruses. 2009; 25:225-227.
13. Depatureaux A, Leoz M, De Oliveira F, et al. Specific diagnosis and follow-up of HIV-1 group O infection: RES-O data [in French]. Med Mal Infect. 2010;40:669-676.
14. Gueudin M, Lemee V, Ferre V, et al. Virologic diagnosis and follow-up of children born to mothers infected by HIV-1 group O. J Acquir Immune Defic Syndr. 2004;36:639-641.
15. Sire JM, Vray M, Merzouk M, et al. Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays. J Acquir Immune Defic Syndr. 2011;56:239-243.
16. Vessiere A, Rousset D, Kfutwah A, et al. Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun. J Acquir Immune Defic Syndr. 2010;53:107-110.
17. Brenner BG, Lowe M, Moisi D, et al. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol. 2011;83:751-759.
18. Garrido C, Geretti AM, Zahonero N, et al. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother. 2010;65: 320-326.
19. Rockstroh JK, Teppler H, Zhao J, et al. Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies. AIDS. 2011;25:1365-1369.
20. Van Baelen K, Van Eygen V, Rondelez E, et al. Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. AIDS. 2008;22: 1877-1880.
21. Charpentier C, Larrouy L, Collin G, et al. In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AIDS. 2010;24:2753-2755.
22. Roquebert B, Damond F, Collin G, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother. 2008;62:914-920.
23. Trevino A, de Mendoza C, Caballero E, et al. Drug resistance mutations in patients infected with HIV-2 living in Spain. J Antimicrob Chemother. 2011;66:1484-1488.
24. Piralla A, Paolucci S, Gulminetti R, et al. HIV integrase variability and genetic barrier in antiretroviral naive and experienced patients. Virol J. 2011;8:149.
25. van de Vijver DA, Wensing AM, Angarano G, et al. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr. 2006;41:352-360.